new glp 1 drugs coming Eli Lilly to seek approval of GLP-1 weight-loss drug this year New research is challenging long-held

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are peptide-derived analogs that were initially investigated to treat type 2 diabetes

Switching to the oral small molecule glucagon-like peptide-1 (GLP-1) orforglipron after taking injectable GLP-1s helped patients maintain mostbut not allof their weight loss, according to a clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.

Recapping the headlines that affected American's health in 2025

It depends on the patient, their body, and their long-term goals

Here, we test whether GLP-1RAs alter alcohols peripheral pharmacokinetics as a potential mechanism of action for their alcohol intake suppressive effects